Medical Care Technologies Inc. Launches AI Platform for Early Basal Cell Carcinoma Detection

Rhea-AI Summary

Medical Care Technologies (OTC:MDCE) has launched an innovative AI platform designed for early detection of basal cell carcinoma (BCC), the most common type of skin cancer. The platform enables at-home screening and monitoring through advanced texture and reflectance analysis technology.

The AI system features sophisticated capabilities including pearly nodule identification, vascular pattern recognition, ulceration tracking, and pixel-level texture classification to distinguish between benign growths and potential carcinomas. This technology aims to address the limited access to dermatology services by providing accessible, non-invasive screening solutions.

Positive

• Introduction of innovative AI platform for early skin cancer detection
• Technology enables non-invasive, at-home screening accessibility
• System provides continuous monitoring and early warning capabilities
• Addresses significant market need with millions of annual BCC cases

Negative

• Early-stage technology without proven clinical validation
• Operating in highly regulated medical device market
• Potential competition from established medical device companies

MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered diagnostics, today unveiled its breakthrough artificial intelligence platform for the detection and monitoring of basal cell carcinoma (BCC), the most common form of skin cancer.

Though rarely fatal, untreated BCC can cause severe disfigurement, local tissue invasion, and costly surgeries. Current detection methods rely heavily on dermatology access, which remains limited for many populations. MDCE's AI platform addresses this gap by enabling scalable, non-invasive, and at-home screening.

Technical Innovation

MDCE's AI system applies texture and reflectance analysis, recognizing hallmark features of BCC including:

• Pearly or translucent nodule identification

• Subsurface vascular pattern recognition (telangiectasia)

• Ulceration tracking over time

• Distinguishing BCC from benign growths through pixel-level texture classification

With continuous longitudinal monitoring, the system can differentiate between harmless lesions and early-stage carcinomas, providing critical alerts for medical follow-up.

"BCC affects millions each year, yet many cases go undiagnosed until they cause permanent damage," said Marshall Perkins, CEO of MDCE. "Our AI tool can help change that equation by bringing early detection directly into the patient's hands."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC: MDCE) develops AI-based solutions for preventive medicine, with a focus on dermatology, neurology, and ocular health.

Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com

---

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What is Medical Care Technologies' (MDCE) new AI platform designed to detect?

MDCE's new AI platform is designed to detect basal cell carcinoma (BCC), the most common form of skin cancer, through non-invasive, at-home screening.

How does MDCE's AI platform detect basal cell carcinoma?

The platform uses texture and reflectance analysis to identify key BCC features including pearly nodules, vascular patterns, ulceration tracking, and pixel-level texture classification to distinguish between benign and cancerous growths.

What problem is MDCE's new AI platform solving?

The platform addresses the limited access to dermatology services by providing accessible, non-invasive, at-home screening for basal cell carcinoma, which often goes undiagnosed until causing permanent damage.

Who is the CEO of Medical Care Technologies (MDCE)?

The CEO of Medical Care Technologies is Marshall Perkins.

What are the key features of MDCE's AI skin cancer detection system?

The key features include pearly nodule identification, subsurface vascular pattern recognition, ulceration tracking, and pixel-level texture classification for distinguishing between harmless lesions and carcinomas.